维普期刊资源整合服务平台（V6.5）

57篇 您的检索式：作者名="Colman H"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death显示文摘	Jiang H Gomez-Manzano C Aoki H Alonso MM Kondo S McCormick F Xu J Kondo Y Bekele BN Colman H Lang FF Fueyo J	2007	中国神经肿瘤杂志2007，5，3：	24
2	胶质瘤干细胞对替莫唑胺敏感性的研究显示文摘目的探讨胶质瘤干细胞(GSC)对替莫唑胺(TMZ)的敏感性及耐药机制。方法新鲜多形性胶质母细胞瘤(GBM)标本培养后获得GSC。免疫荧光技术检测未分化GSC的CD133及分化生长GSC的GFAP的表达,MTS法检测对替莫唑胺的敏感性,流式细胞技术对CD133阳性细胞的比例进行定量,荧光标记的甲基化特异性PCR分析MGMT启动子区域的甲基化状态,Western blot检测抑癌基因PTEN的表达。结果(1)5例GBM标本中成功获得GSC,符合肿瘤干细胞定义。(2)5个GSC细胞株多数对TMZ不敏感。其中,T509的半数抑制浓度(IC50)为22.3μmol/L(敏感),T411的IC50为286.3μmol/L(中度敏感),其余3个细胞株T402,T405及T509的IC50皆大于1000μmol/L(不敏感)。(3)CD133阳性细胞比例大于10%的GSC细胞株对TMZ不敏感。(4)MGMT启动子区域呈去甲基化状态的GSC对TMZ不敏感或仅为中度敏感。(5)5个GSC细胞株中,PTEN表达水平差异大,与GSC对TMZ的敏感性无明显关联。结论GSC对TMZ普遍耐药,与MGMT启动子区域甲基化状态及CD133阳性细胞有关,而与PTEN蛋白表达水平无明显关联。	赛克 WANG Shu-zhen Popoff S Yung WK Colman H 陈忠平	2009	中华神经外科杂志2009，25，10：	7
3	IDH1 and IDH2 mutations in gliomas显示文摘	Cohen AL Holmen SL Colman H	2013	Curr Neurol Neurosci Rep2013，13，5：	1
4	Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis 显示文摘	Zhang W Ke H Colman RW	2002	Mol Pharmacol2002，62，3：	1
5	Contact system: a vascular biology modulator with anticoagulant, profibr inolytic, antiadhesive, and proinflammatory attrlbutes显示文摘	Colman R M Schmaier A H	1997	Blood1997，7，90：	1
6	Success and limitations of a naked plasmid transfection protocol keratinocyte growth factor-1 to enhance cutaneous wound healing 显示文摘	Colman K Byrnes MB Faisal H	2001	Wound Repair Regener2001，9，5：	1
7	Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site- directed mutagenesis 显示文摘	Zhang W Ke H Colman R W	2002	Mol Pharmacol2002，62，3：	1
8	Brain tumor stem cell 显示文摘	Sulman E Aldape K Colman H	2008	Curr Probl Cancer2008，32，3：	1
9	Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial flbrilla-tion and prior stroke or transient ischemic attack 显示文摘	Arima H Hart RG Colman S	2005	Stroke2005，36，：	1
10	Urotensin Ⅱ: a novel vasoactive mediator linked to chronic liver disease and portal hypertension 显示文摘	Kemp W Krum H Colman J	2007	Liver Int2007，27，9：	1
11	Molecular predictors in glioblastoma: toward personalized therapy 显示文摘	Colman H Aldape K	2008	Arch Neuro12008，65，7：	1
12	Framework for COPD forecas- ting in the UK using weather and climate change predictions 显示文摘	Deborah H Colman A James P	2009	Earth Environ Sci2009，6，：	1
13	A multigene predictor of outcome in glioblastoma显示文摘	Colman H Zhang L Sulman EP		0，，：	1
14	Framework for COPD forecasting in the UK using weather and climate change predictions显示文摘	Deborah H Colman A James P		0，，01：	1
15	A multigene predictor of outcome in glioblastoma显示文摘	Colman H Zhang L Sulman EP	2010	Neuro Oncol2010，12，1：	1
16	Framework for COPD forecasting in the UK using weather and climate change predictions显示文摘	Deborah H Colman A James P	2009	Earth Environ Sci2009，6，14：	1
17	Urotensin Ⅱ:a novel vasoactive mediator linked to chronic liver disease and portal hypertension显示文摘	Kemp W Krum H Colman J	2007	Liver Int2007，27，：	1
18	Urotensin Ⅱ:a novel vasoactive mediator linked to chronic liver disease and portal hypertension显示文摘	Kemp W Krum H Colman J	2007	Liver Int2007，27，9：	1
19	Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack显示文摘	Arima H Hart RG Colman S	2005	Stroke2005，36，：	1
20	Genetic variegation of clonal architecture and propagating cells in leukaemia显示文摘	Anderson K Lutz C van Delft FW Bateman CM Guo YP Colman SM Kempski H Moorman AV Titley I Swansbury J Kearney L Enver T Greaves M		0，，7330：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示